Applied Therapeutics Inc. reported its financial results for the third quarter ended September 30, 2025. The company announced cash and cash equivalents of $11.9 million as of September 30, 2025, compared to $79.4 million at December 31, 2024. Applied Therapeutics provided updates on its regulatory strategy for govorestat, including a completed meeting with the FDA regarding a potential NDA submission for the treatment of CMT-SORD and plans to submit a meeting request for further discussion on a potential Phase 3 trial. A meeting with the FDA is also scheduled in the fourth quarter of 2025 to discuss govorestat for Classic Galactosemia. Additionally, new data on govorestat for PMM2-CDG was published and presented at the 2025 ASHG Annual Meeting. The company also announced a leadership transition, with John Johnson stepping down as Executive Chairman and director for personal reasons.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Applied Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-278814), on November 13, 2025, and is solely responsible for the information contained therein.
Comments